Discover why LeMaitre's expansion in the peripheral vascular disease market and strong dividend growth make it an appealing ...

LeMaitre Vascular, Inc. (NASDAQ:LMAT – Free Report) – Stock analysts at Barrington Research upped their FY2024 earnings per ...

周五，Stifel对LeMaitre Vascular (NASDAQ:LMAT)股票进行了更新，将公司股票目标价从95美元上调至100美元，同时维持买入评级。这一调整是基于LeMaitre的第三季度表现，分析师将其描述为"令人鼓舞的超预期表现和上调指引"，强调公司的增长驱动因素正在达到或超过预期。

BURLINGTON, Mass., Nov. 01, 2024 (GLOBE NEWSWIRE) -- (Nasdaq:LMAT) announced today that management will be participating in ...

周二，Cantor Fitzgerald开始对专注于外周血管疾病治疗医疗设备和服务的公司LeMaitre Vascular (NASDAQ:LMAT)进行覆盖，给予中性评级，12个月股票目标价为$96.00。该公司认识到LeMaitre Vascular在估值约$50亿的外周血管设备市场的细分市场中具有强劲地位。 LeMaitre Vascular在市场中的地位被认为可能允许其因专业化产品而持续提 ...

The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $95.25, a high ...

Lemaitre Vascular (LMAT – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Daniel ...

Third Quarter 2024 Results Key Financial Results Revenue: US$54.8m (up 16% from ...

Lemaitre Vascular ( (LMAT) ) has released its Q3 earnings. Here is a breakdown of the information Lemaitre Vascular presented to its investors.

BURLINGTON, Mass., Oct. 31, 2024 (GLOBE NEWSWIRE) -- LeMaitre (Nasdaq:LMAT), a provider of vascular devices, implants, and ...

Straftat's 1v1 gunfights are fun enough on their own, but its massive map roster and array of inventive weapons instantly ...

For the current quarter ending in December, LeMaitre said it expects revenue in the range of $54.9 million to $56.9 million. The company expects full-year earnings to be $1.91 to $1.96 per share, with ...